177 related articles for article (PubMed ID: 38200213)
1. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.
Zhou S; Wang S; Xiang J; Han Z; Wang W; Zhang S; Opara NC; Ju S; Cui Y; Wang YC
Abdom Radiol (NY); 2024 Feb; 49(2):471-483. PubMed ID: 38200213
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis.
Kim DW; Choi SH; Kim SY; Byun JH; Lee SS; Park SH; Kim KW
Hepatol Int; 2020 Dec; 14(6):1009-1022. PubMed ID: 33146841
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis.
Feng Z; Zhao H; Guan S; Wang W; Rong P
Liver Int; 2021 May; 41(5):1117-1128. PubMed ID: 33647177
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.
Chen X; Li M; Guo R; Liu W; Li J; Zong X; Chen Q; Wang J
Abdom Radiol (NY); 2022 Jun; 47(6):2057-2070. PubMed ID: 35312822
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment.
Rimola J; Davenport MS; Liu PS; Brown T; Marrero JA; McKenna BJ; Hussain HK
Abdom Radiol (NY); 2019 Feb; 44(2):549-558. PubMed ID: 30218239
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of CT versus MRI Liver Imaging Reporting and Data System category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies.
Kim YY; Lee S; Shin J; Son WJ; Roh YH; Hwang JA; Lee JE
Eur Radiol; 2022 Oct; 32(10):6723-6729. PubMed ID: 35849177
[TBL] [Abstract][Full Text] [Related]
7. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA.
Son J; Hwang SH; Park S; Han K; Chung YE; Choi JY; Kim MJ; Park MS
Invest Radiol; 2019 Aug; 54(8):494-499. PubMed ID: 31094878
[TBL] [Abstract][Full Text] [Related]
8. Extracellular contrast agent-enhanced MRI is as effective as gadoxetate disodium-enhanced MRI for predicting microvascular invasion in HCC.
Sheng L; Wei H; Yang T; Yang J; Zhang L; Zhu X; Jiang H; Song B
Eur J Radiol; 2024 Jan; 170():111200. PubMed ID: 37995512
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.
Li J; Wang J; Lei L; Yuan G; He S
Eur Radiol; 2019 Dec; 29(12):6519-6528. PubMed ID: 31250172
[TBL] [Abstract][Full Text] [Related]
10. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI.
Yim JH; Kim YK; Min JH; Lee J; Kang TW; Lee SJ
Abdom Radiol (NY); 2019 Jul; 44(7):2366-2376. PubMed ID: 30847566
[TBL] [Abstract][Full Text] [Related]
13. Is Gadoxetic Acid Disodium (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging an Accurate Diagnostic Method for Hepatocellular Carcinoma? A Systematic Review with Meta-Analysis.
Yinzhong W; Xiaoxue T; Jinhui T; Pengcheng Y; Xiaoying L; Junqiang L
Curr Med Imaging; 2022; 18(6):633-647. PubMed ID: 34533447
[TBL] [Abstract][Full Text] [Related]
14. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis.
Pan J; Tao Y; Chi X; Yang L; Zhao Y; Chen F
Eur Radiol; 2022 Aug; 32(8):5134-5143. PubMed ID: 35267090
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation.
Jhaveri KS; Babaei Jandaghi A; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G
Cancer Imaging; 2023 Feb; 23(1):22. PubMed ID: 36841796
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.
Liu X; Jiang H; Chen J; Zhou Y; Huang Z; Song B
Liver Transpl; 2017 Dec; 23(12):1505-1518. PubMed ID: 28886231
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
18. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria.
Yoon JK; Han DH; Lee S; Choi JY; Choi GH; Kim DY; Kim MJ
Cancer Res Treat; 2023 Jul; 55(3):939-947. PubMed ID: 36791769
[TBL] [Abstract][Full Text] [Related]
20. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
